Product
CKD-702
1 clinical trial
1 indication
Indication
Stomach CancerClinical trial
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or METStatus: Recruiting, Estimated PCD: 2024-12-31